Bexagliflozin extended-release tablet, SGLT2 inhibitor formulation

ChangeBridge: Patent Grants - Therapeutics (A61P)

Published April 7th, 2026

Detected April 7th, 2026

Summary

The USPTO granted patent US12594243B2 to TheracosBio, LLC for an extended-release tablet formulation of the SGLT2 inhibitor bexagliflozin. The patent covers formulations designed to achieve lower peak plasma concentrations (Cmax) compared to immediate-release forms while maintaining therapeutic drug levels over extended periods. The patent contains 7 claims and provides intellectual property protection for the drug delivery technology through 2040.

View original document View source feed page

What changed

The USPTO issued patent US12594243B2 (B2 grant) to TheracosBio, LLC covering an extended-release tablet formulation of the SGLT2 inhibitor bexagliflozin. The formulation improves the pharmacokinetic profile by achieving lower peak plasma concentrations while maintaining therapeutic drug levels, potentially enabling lower dosing while preserving pharmacological efficacy. The patent claims cover the specific extended-release tablet composition and methods of using the formulation for treating conditions amenable to SGLT2 inhibition.

For pharmaceutical companies and potential competitors, this patent establishes intellectual property barriers around bexagliflozin extended-release technology. Third parties developing similar extended-release formulations for SGLT2 inhibitors should conduct freedom-to-operate analyses to assess potential infringement risks. The patent's 7 claims provide TheracosBio with market exclusivity for this specific drug delivery approach.

What to do next

Monitor for freedom-to-operate implications if developing competing SGLT2 inhibitor formulations
Review patent claims when assessing product development strategies

Source document (simplified)

← USPTO Patent Grants

Pharmaceutical formulations

Grant US12594243B2 Kind: B2 Apr 07, 2026

Assignee

THERACOSBIO, LLC

Inventors

Feng Wang, Ankit Shrivastava, Rina Shah, Brian Seed, Vinay Patil, Michael J. Hadd, Fuxia Dong, Vipan Dhall, Chunfeng Dai, Joseph Ho-Lun Chau, Qiuhua Cai

Abstract

The pharmacokinetic profile of the SGLT2 inhibitor bexagliflozin can be improved by formulating it as an extended release tablet. Compared with standard immediate-release dosage forms these tablets can permit a lower peak plasma concentration, Cmax, while maintaining plasma concentrations at therapeutic levels for a desired period. This can be used, for instance, to administer lower doses while still providing the same pharmacological effect.